Endo Pa Repeat Screen Medication

---
name: endo-pa-repeat-screen-medication
description: Recommends withdrawing interfering medications and repeating aldosterone-to-renin ratio screening when initial screen is negative but clinical suspicion remains due to hypokalemia or medication interference. Trigger phrases include "initial screen negative", "hypokalemia", "resistant hypertension", and use of MRAs, ACE inhibitors, ARBs, beta-blockers, clonidine, or alpha-methyldopa.
---

# Repeat PA screening after withdrawing interfering medications if initial screen negative

## STEP 1 — Gather Information
Collect morning seated serum/plasma aldosterone and plasma renin (concentration or activity), serum potassium, and medication list (including MRAs, ENaC inhibitors, ACE inhibitors, ARBs, beta-blockers, centrally acting alpha-agonists). Assess for hypokalemia, resistant hypertension, and pretest probability of PA.

## STEP 2 — Rule In / Rule Out
Is the initial aldosterone-to-renin ratio (ARR) screen negative or positive?

## STEP 3 — Classify or Stratify
If screen negative, evaluate for false-negative contributors: hypokalemia or use of MRAs, ENaC inhibitors, ACE inhibitors, ARBs. If screen positive, evaluate for false-positive contributors: use of beta-blockers or centrally acting alpha-agonists (clonidine, alpha-methyldopa) that suppress renin.

## STEP 4 — Decide
For negative screen with false-negative contributors, correct potassium to lab reference range and withdraw interfering medications (4 weeks for MRAs/ENaC inhibitors, 2 weeks for ACE inhibitors/ARBs) if safe and feasible, then repeat ARR screen. For positive screen with false-positive contributors, withdraw beta-blockers or centrally acting alpha-agonists for 2 weeks if safe and feasible, then repeat ARR screen.

## Clinical Guardrails / Mimics / Pitfalls
Do not rely on hypokalemia alone to exclude PA; do not repeat screening without correcting potassium or withdrawing medications when indicated; do not withdraw medications that are unsafe to stop (e.g., in heart failure) without cardiology input; do not assume a negative screen rules out PA in patients with moderate-to-high pretest probability; avoid repeating screen too soon before medication washout is complete.

## Concrete Clinical Example
A 52-year-old with hypertension and hypokalemia (K+ 3.0 mmol/L) has an initial ARR of 15 (negative). She is taking spironolactone 25 mg daily for hypertension. After correcting potassium with supplementation and holding spironolactone for 4 weeks, repeat ARR is 35 (positive), leading to confirmatory testing and diagnosis of an aldosterone-producing adenoma.

**Source:** Primary Aldosteronism: An Endocrine Society Clinical Practice Guideline, Endocrine Society, 2025, https://doi.org/10.1210/clinem/dgaf284